Methods of Pharmacoeconomic Evaluation of Psychopharmacologic Therapies for Patients with Schizophrenia

Overview

Journal J Psychiatry Neurosci

Specialty Psychiatry

Date 1997 Jul 1

PMID 9262048

Citations 7

Authors

D A Revicki

Affiliations

Soon will be listed here.

Abstract

The pharmacoeconomic evaluation of psychopharmacologic treatments for patients with schizophrenia requires attention to the clinical and quality of life effects of the therapy, as well as its impact on the use and cost of medical services. The results of pharmacoeconomic studies help clinicians and health care decision makers determine treatments that provide the most benefit to patient functioning and well-being at the most acceptable medical cost. Various research designs and methods have been used to evaluate the cost-effectiveness of antipsychotic drugs, including retrospective studies, prospective studies, and clinical decision analysis models. This article summarizes these research designs and their strengths and weaknesses in the evaluation of antipsychotic drugs for treating schizophrenia.

Citing Articles

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Edgell E, Andersen S, Johnstone B, Dulisse B, Revicki D, Breier A Pharmacoeconomics. 2001; 18(6):567-79.

PMID: 11227395 DOI: 10.2165/00019053-200018060-00004.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster R, Olney R, Plosker G Drugs. 2001; 61(1):111-61.

PMID: 11217867 DOI: 10.2165/00003495-200161010-00011.

An evaluation of psychometric properties of the client's questionnaire of the Wisconsin Quality of Life Index-Canadian version (CaW-QLI).

Diaz P, Mercier C, Hachey R, Caron J, Boyer G Qual Life Res. 1999; 8(6):509-14.

PMID: 10548866 DOI: 10.1023/a:1008970321690.

Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Foster R, Goa K Pharmacoeconomics. 1999; 15(6):611-40.

PMID: 10538333 DOI: 10.2165/00019053-199915060-00008.

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Hamilton S, Revicki D, Edgell E, Genduso L, Tollefson G Pharmacoeconomics. 1999; 15(5):469-80.

PMID: 10537964 DOI: 10.2165/00019053-199915050-00005.

References

Rosen A, Hadzi-Pavlovic D, Parker G . The life skills profile: a measure assessing function and disability in schizophrenia. Schizophr Bull. 1989; 15(2):325-37. DOI: 10.1093/schbul/15.2.325. View

Revicki D, Luce B, Weschler J, Brown R, Adler M . Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry. 1990; 41(8):850-4. DOI: 10.1176/ps.41.8.850. View

HONIGFELD G, PATIN J . A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry. 1990; 41(8):882-5. DOI: 10.1176/ps.41.8.882. View

Drummond M, Davies L . Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care. 1991; 7(4):561-73. DOI: 10.1017/s0266462300007121. View

Laupacis A, Feeny D, Detsky A, Tugwell P . How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146(4):473-81. PMC: 1488412. View

Davies L, Drummond M . Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry. 1993; 162:38-42. DOI: 10.1192/bjp.162.1.38. View

Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G . A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13(1):25-40. View

Meltzer H, Cola P, Way L, Thompson P, Bastani B, Davies M . Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993; 150(11):1630-8. DOI: 10.1176/ajp.150.11.1630. View

Becker M, Diamond R, Sainfort F . A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res. 1993; 2(4):239-51. DOI: 10.1007/BF00434796. View

10.

Addington D, Jones B, Bloom D, Chouinard G, Remington G, Albright P . Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther. 1993; 15(5):917-26. View

11.

Rosenheck R, Massari L, Frisman L . Who should receive high-cost mental health treatment and for how long?. Schizophr Bull. 1993; 19(4):843-52. DOI: 10.1093/schbul/19.4.843. View

12.

Marder S, Meibach R . Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151(6):825-35. DOI: 10.1176/ajp.151.6.825. View

13.

Reid W, Mason M, Toprac M . Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry. 1994; 45(3):261-4. DOI: 10.1176/ps.45.3.261. View

14.

Revicki D, Luce B . Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull. 1995; 31(1):57-65. View

15.

Wyatt R, Henter I, Leary M, Taylor E . An economic evaluation of schizophrenia--1991. Soc Psychiatry Psychiatr Epidemiol. 1995; 30(5):196-205. PMC: 4300526. DOI: 10.1007/BF00789054. View

16.

Jonsson D, Walinder J . Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand. 1995; 92(3):199-201. DOI: 10.1111/j.1600-0447.1995.tb09568.x. View

17.

Essock S, Hargreaves W, Dohm F, Goethe J, Carver L, Hipshman L . Clozapine eligibility among state hospital patients. Schizophr Bull. 1996; 22(1):15-25. DOI: 10.1093/schbul/22.1.15. View

18.

Glazer W, Ereshefsky L . A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry. 1996; 57(8):337-45. View

19.

Umbricht D, Kane J . Risperidone: efficacy and safety. Schizophr Bull. 1995; 21(4):593-606. DOI: 10.1093/schbul/21.4.593. View

20.

Lehman A, Carpenter Jr W, Goldman H, Steinwachs D . Treatment outcomes in schizophrenia: implications for practice, policy, and research. Schizophr Bull. 1995; 21(4):669-75. DOI: 10.1093/schbul/21.4.669. View